Furthermore, IL-6 levels showed a trend of increasing with worsening prognostic category, with a statistically significant difference observed between the adverse- and favorable-risk groups ( Figure 1 A).
← all excerpts
Targeting bone marrow mesenchymal stromal cell-derived IL-6 to overcome acute myeloid leukemia chemoresistance.
1
—
—